Introduction to Medical Mycology

  • Arunaloke ChakrabartiEmail author
  • Nandini Sethuraman


Fungi are ubiquitous and nearly 1.5 million fungal species exist in the universe, but only few fungi were known to be pathogenic to humans. The temperature of 37 °C, low redox potential in tissues and immune barrier prevent majority of fungi from invading human hosts. However with the change of host environment due to co-morbidities, several saprophytic fungi get the opportunity to adapt to human tissue. The impact of modern medical interventions and fungi adapting to this environment are reasons why many fungi are now known to cause invasive human disease. Fungal infection in humans varies from superficial colonization to invasive diseases and allergic manifestations; each group associated with unique risk factors. Impact of the global burden of fungal infections is often overlooked and estimates are often extrapolations of limited available data. There is also wide variation in the geographical niches occupied by fungi across the world for reasons largely unknown. Natural disasters also contribute to the upsurge of invasive fungal infections. The severity of infection closely parallels a suppression of immunity. Invasive fungal infections are important causes of morbidity and mortality of hospitalized patients. Diagnosis of these fungal infections is often a challenge due to poor sensitivity, specificity and long turnaround times of conventional diagnostic methods. Availability of advanced, rapid technologies is sparse in the majority of laboratories in developing countries. Several biomarkers and molecular techniques are being studied to reduce these turnaround times. In spite of availability of new antifungals, therapy is often empirical due to rapid progression of disease and non-availability of early diagnosis. There is no ideal antifungal agent. Limited spectrum, drug-interaction, toxicity and cost of antifungals are limiting factors. A brief description of these challenges is presented in this introductory chapter.



The authors would like to thank Dr. Ajay Padmanaban for the illustrations.


  1. 1.
    Casadevall A (2012) Amoeba provide insight into the origin of virulence in pathogenic fungi. Adv Exp Med Biol 710:1–10CrossRefPubMedGoogle Scholar
  2. 2.
    Kenyon C et al (2013) A dimorphic fungus causing disseminated infection in South Africa. N Engl J Med 369(15):1416–1424CrossRefPubMedGoogle Scholar
  3. 3.
    Malik R et al (2016) Disseminated Emmonsia pasteuriana infection in India: a case report and a review. Mycoses 59(2):127–132CrossRefPubMedGoogle Scholar
  4. 4.
    Whittaker RH (1969) New concepts of kingdoms of organisms. Science 163(3863):150–160CrossRefPubMedGoogle Scholar
  5. 5.
    Ruggiero MA et al (2015) A higher level classification of all living organisms. PLoS One 10(4):1–60CrossRefGoogle Scholar
  6. 6.
    De Hoog GS et al (2015) Name changes in medically important fungi and their implications for clinical practice. J Clin Microbiol 53(4):1056–1062CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Schmalreck AF et al (2014) Phylogenetic relationships matter: antifungal susceptibility among clinically relevant yeasts. Antimicrob Agents Chemother 58(3):1575–1585CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Havlickova B, Czaika VA, Friedrich M (2008) Epidemiological trends in skin mycoses worldwide. Mycoses 51(suppl 4):2–15CrossRefPubMedGoogle Scholar
  9. 9.
    Sobel JD (2016) Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 214(1):15–21CrossRefPubMedGoogle Scholar
  10. 10.
    Sobel JD (2007) Vulvovaginal candidosis. Lancet 369(9577):1961–1971CrossRefPubMedGoogle Scholar
  11. 11.
    Brown GD et al (2012) Hidden killers: human fungal infections. Sci Transl Med 4(165):165rv13CrossRefPubMedGoogle Scholar
  12. 12.
    Vallabhaneni S et al (2016) The global burden of fungal diseases. Infect Dis Clin N Am 30(1):1–11CrossRefGoogle Scholar
  13. 13.
    Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20(1):133–163CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Trick WE et al (2002) Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35(5):627–630CrossRefPubMedGoogle Scholar
  15. 15.
    Bhansali A et al (2004) Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. Postgrad Med J 80(949):670–674CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Supabandhu J et al (2008) Isolation and identification of the human pathogen Pythium insidiosum from environmental samples collected in Thai agricultural areas. Med Mycol 46(1):41–52CrossRefPubMedGoogle Scholar
  17. 17.
    Al-Tawfiq JA, Boukhamseen A (2011) Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei (formerly Ramichloridium mackenziei): case presentation and literature review. J Infect Public Health 4(2):96–102CrossRefPubMedGoogle Scholar
  18. 18.
    Nucci M et al (2013) Increased incidence of invasive fusariosis with cutaneous portal of entry, Brazil. Emerg Infect Dis 19(10):1567–1572CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Slavin MA (2011) Scedosporiosis. Mycoses 54:26Google Scholar
  20. 20.
    Fahal AH, Sabaa AH (2010) Mycetoma in children in Sudan. Trans R Soc Trop Med Hyg 104(2):117–121CrossRefPubMedGoogle Scholar
  21. 21.
    Pfaller MA et al (2011) Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY antimicrobial surveillance program, 2008-2009. Antimicrob Agents Chemother 55(2):561–566CrossRefPubMedGoogle Scholar
  22. 22.
    Chakrabarti A et al (2001) Outbreak of Pichia anomala infection in the pediatric service of a tertiary-care center in northern India. J Clin Microbiol 39(5):1702–1706CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Repetto EC, Giacomazzi CG, Castelli F (2012) Hospital-related outbreaks due to rare fungal pathogens: a review of the literature from 1990 to June 2011. Eur J Clin Microbiol Infect Dis 31(11):2897–2904CrossRefPubMedGoogle Scholar
  24. 24.
    Kainer MA et al (2012) Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med 367(23):2194–2203CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Litvintseva AP et al (2014) Whole-genome analysis of Exserohilum rostratum from an outbreak of fungal meningitis and other infections. J Clin Microbiol 52(9):3216–3222CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Romani L (2011) Immunity to fungal infections. Nat Rev Immunol 11(4):275–288CrossRefPubMedGoogle Scholar
  27. 27.
    Aimanianda V et al (2009) Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature 460(7259):1117–1121CrossRefPubMedGoogle Scholar
  28. 28.
    Mora-Montes HM et al (2011) Recognition and blocking of innate immunity cells by Candida albicans chitin. Infect Immun 79(5):1961–1970CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Oksuz S et al (2007) Phospholipase and proteinase activities in different Candida species isolated from anatomically distinct sites of healthy adults. Jpn J Infect Dis 60(5):280–283PubMedGoogle Scholar
  30. 30.
    Guarner J, Brandt ME (2011) Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev 24(2):247–280CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    De Pauw B et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG). Clin Infect Dis 46(12):1813–1821CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Leung AN et al (1999) Pulmonary infections after bone marrow transplantation: clinical and radiographic findings. Radiology 210(3):699–710CrossRefPubMedGoogle Scholar
  33. 33.
    Thomas CF, Limper AH (2004) Pneumocystis pneumonia. N Engl J Med 350(24):2487–2498CrossRefPubMedGoogle Scholar
  34. 34.
    Bruno C et al (2007) Comparison of CT features of Aspergillus and bacterial pneumonia in severely neutropenic patients. J Thorac Imaging 22(2):160–165CrossRefPubMedGoogle Scholar
  35. 35.
    Kauffman CA (2005) Candiduria. Clin Infect Dis 41(Suppl 6):S371–S376CrossRefPubMedGoogle Scholar
  36. 36.
    Arvanitis M et al (2014) Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev 27(3):490–526CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Neely LA et al (2013) T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med 5(182):182ra54CrossRefPubMedGoogle Scholar
  38. 38.
    Dou YH et al (2013) The role of procalcitonin in the identification of invasive fungal infection-a systemic review and meta-analysis. Diagn Microbiol Infect Dis 76(4):464–469CrossRefPubMedGoogle Scholar
  39. 39.
    Karageorgopoulos DE et al (2011) β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 52(6):750–770CrossRefPubMedGoogle Scholar
  40. 40.
    Bernardes-Engemann AR et al (2015) Validation of a serodiagnostic test for sporotrichosis: a follow-up study of patients related to the Rio de Janeiro zoonotic outbreak. Med Mycol 53(1):28–33CrossRefPubMedGoogle Scholar
  41. 41.
    Harrison E et al (2010) Aspergillus DNA contamination in blood collection tubes. Diagn Microbiol Infect Dis 67(4):392–394CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Loeffler J et al (2015) Analytical comparison of in vitro spiked human serum and plasma for PCR-based detection of Aspergillus fumigatus DNA: a study by the European Aspergillus PCR initiative. J Clin Microbiol 53(9):2838–2845CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Scheel CM et al (2014) Development of a loop-mediated isothermal amplification method for detection of Histoplasma capsulatum DNA in clinical samples. J Clin Microbiol 52(2):483–488CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49(9):3640–3645CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Pappas PG et al (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 62(4):e1–50CrossRefPubMedGoogle Scholar
  46. 46.
    Albataineh MT et al (2016) Update from the laboratory: clinical identification and susceptibility testing of fungi and trends in antifungal resistance. Infect Dis Clin N Am 30(1):13–35CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Medical MicrobiologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia
  2. 2.Department of MicrobiologyApollo hospitalsChennaiIndia

Personalised recommendations